When and how NK cell-induced programmed cell death benefits immunological protection against intracellular pathogen infection - José E Belizário, Jennifer M Neyra, Maria Fernanda Setúbal Destro Rodrigues, 2018
Issels Immuno-Oncology - LAK Cell Therapy for the Treatment of Cancer
Natural Killer Cell Response - an overview | ScienceDirect Topics
Oxidized-Desialylated Low-Density Lipoprotein Inhibits the Antitumor Functions of Lymphokine Activated Killer Cells
Cell-based immunotherapy
Frontiers | Next Generation Natural Killer Cells for Cancer Immunotherapy
AAAAI
Cancers | Free Full-Text | Arming Immune Cells for Battle: A Brief Journey through the Advancements of T and NK Cell Immunotherapy
Cancers | Free Full-Text | The Function of NK Cells in Tumor Metastasis and NK Cell-Based Immunotherapy
Frontiers | All About (NK Cell-Mediated) Death in Two Acts and an Unexpected Encore: Initiation, Execution and Activation of Adaptive Immunity
Innate or non-specific immunity
A Combined Lymphokine-activated Killer (LAK) Cell Immunotherapy and Adenovirus-p53 Gene Therapy for Head and Neck Squamous Cell Carcinoma | Anticancer Research
Cytokine-induced killer (CIK) cells: from basic research to clinical translation | Cancer Communications | Full Text
Immunology intro | PPT
JaypeeDigital | eBook Reader
The immunomodulatory effects of gentamicin, imipenem, piperacillin and amphotericin B on LAK effector function in vitro1
LYMPHOKINE-ACTIVATED KILLER (LAK) CELLS I. Differential Recovery of LAK, Natural Killer Cells, and Cytotoxic T Lymphocytes af
Tumor immunology | PPT
Natural killer (NK) and lymphokine-activated killer (LAK) cell functions from healthy dogs and 29 dogs with a variety of spontaneous neoplasms | springermedizin.de
Exploring the NK cell platform for cancer immunotherapy | Nature Reviews Clinical Oncology
Antigen-independent killer cells prepared for adoptive immunotherapy: One source, divergent protocols, diverse nomenclature - ScienceDirect
Natural Killer Cells | Clinical Gate
Generation of lymphokine-activated killer cells: synergy between tumor necrosis factor and interleukin 2.
The emerging role of off-the-shelf engineered natural killer cells in targeted cancer immunotherapy: Molecular Therapy - Oncolytics
Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity | Journal for ImmunoTherapy of Cancer
